甘露特钠获评《阿尔茨海默病多元康复干预中国专家共识》高证据质量和强推荐

Core Viewpoint - The innovative drug Mannothe Sodium (brand name: Jiuyiqi) developed by Green Valley (Shanghai) Pharmaceutical Technology Co., Ltd. has received strong recommendations and high evidence quality rating in the "Alzheimer's Disease Multidimensional Rehabilitation Intervention Chinese Expert Consensus (2025)" [1][2] Group 1: Drug Efficacy and Recommendations - Mannothe Sodium is recognized as the first oligosaccharide drug targeting the gut-brain axis for Alzheimer's treatment, showing significant improvement in cognitive function and daily living abilities for mild to moderate Alzheimer's patients [2][3] - The drug has been recommended for its ability to improve cognitive function and daily living abilities in patients, with long-term use potentially delaying disease progression [2][3] - The consensus document includes 23 consensus opinions across four areas: prevention, treatment, rehabilitation, and care, emphasizing the drug's clinical relevance and evidence transparency [1][2] Group 2: Clinical Research and Safety - Two post-marketing clinical studies (GV-971-PMS-A and GV-971-PMS-B) involving 3,300 patients over two years indicate that patients treated with Mannothe Sodium showed significant cognitive and daily living improvements compared to baseline [3] - The drug demonstrated a safety profile without potential risks when used in elderly patients with common comorbidities and concurrent medications [3] - The final data results from these studies are expected to be presented at international academic conferences later this year [3] Group 3: Company Background - Green Valley Pharmaceutical Technology focuses on innovative cognitive health solutions, particularly in the treatment of cognitive disorders such as Alzheimer's disease, vascular dementia, and Parkinson's disease [8] - The company aims to enhance human cognitive health through research on the gut-brain axis and artificial intelligence, establishing a cognitive health industry ecosystem [8] - Mannothe Sodium has broken a 17-year drought of new drug approvals in the field and was included in the national medical insurance directory in 2021 [8]